down arrow

Edwards Lifesciences Corp.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US28176E1082
USD
85.78
1.8 (2.14%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

84.0085.96

52 Week

65.9487.32
Valuation
Technical
Day's Volume

CASH

1.19 M

Shareholding (Mar 2025)

FII

32.22%

Held by 502 FIIs

DII

30.8%

Held by 94 DIIs

Promoter

1.09%

How big is Edwards Lifesciences Corp.?

22-Jun-2025

As of Jun 18, Edwards Lifesciences Corp. has a market capitalization of $44.23 billion, with net sales of $5.54 billion and a net profit of $1.44 billion for the latest four quarters. The balance sheet shows shareholder's funds of $10.00 billion and total assets of $13.06 billion.

As of Jun 18, Edwards Lifesciences Corp. has a market capitalization of 44,225.77 million, categorizing it as a Large Cap company.<BR><BR>As of Jun 18, the company reported net sales of 5,538.80 million and a net profit of 1,437.10 million for the latest four quarters.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 9,998.40 million and total assets of 13,055.30 million.

Read More

What does Edwards Lifesciences Corp. do?

22-Jun-2025

Edwards Lifesciences Corporation manufactures heart valve systems and repair products, with net sales of $1.413 billion and a market cap of approximately $44.23 billion as of March 2025. The company operates in the Pharmaceuticals & Biotechnology industry and has a P/E ratio of 30.00.

Overview:<BR>Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products, operating within the Pharmaceuticals & Biotechnology industry and categorized as a large-cap company.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,413 Million (Quarterly Results - Mar 2025)<BR>- Net Profit: 364 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 44,225.77 Million (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 30.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.32<BR>- Return on Equity: 15.23%<BR>- Price to Book: 4.37<BR><BR>Contact Details:<BR>- Address: 1 Edwards Way, IRVINE CA: 92614-5688<BR>- Tel: 1 949 2502500<BR>- Website: https://www.edwards.com

Read More

Who are in the management team of Edwards Lifesciences Corp.?

22-Jun-2025

As of March 2022, the management team of Edwards Lifesciences Corp. includes Chairman and CEO Michael Mussallem, Lead Independent Director Martha Marsh, Directors Paul LaViolette and Ramona Sequeira, and Independent Directors Kieran Gallahue and William Link. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Edwards Lifesciences Corp. includes the following individuals:<BR><BR>- Mr. Michael Mussallem, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Ms. Martha Marsh, who is the Lead Independent Director.<BR>- Mr. Paul LaViolette, who holds the position of Director.<BR>- Ms. Ramona Sequeira, also a Director.<BR>- Mr. Kieran Gallahue, who is an Independent Director.<BR>- Dr. William Link, another Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is Edwards Lifesciences Corp. overvalued or undervalued?

20-Sep-2025

As of July 24, 2025, Edwards Lifesciences Corp. is considered overvalued with a P/E ratio of 30 and has underperformed the S&P 500, returning -20.14% over three years compared to the index's 70.41% gain.

As of 24 July 2025, the valuation grade for Edwards Lifesciences Corp. has moved from fair to expensive, indicating a shift towards overvaluation. The company appears overvalued based on key metrics, including a P/E ratio of 30, a Price to Book Value of 4.62, and an EV to EBITDA ratio of 26.46. In comparison to peers, Agilent Technologies, Inc. has a more favorable P/E ratio of 27.42, while DexCom, Inc. is also considered expensive with a P/E of 53.65.<BR><BR>The recent stock performance further supports this valuation narrative, as Edwards Lifesciences has underperformed against the S&P 500 over multiple periods, including a -20.14% return over three years compared to the S&P 500's 70.41%. This trend highlights the challenges the company faces in delivering shareholder value relative to broader market performance.

Read More

Is Edwards Lifesciences Corp. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Edwards Lifesciences Corp. shows a mildly bullish trend overall, despite mixed signals from various indicators, with a 1.93% return over the past month, underperforming the S&P 500's 2.32%.

As of 24 October 2025, the technical trend for Edwards Lifesciences Corp. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and KST show a mildly bearish trend. Monthly indicators present a mixed view with the MACD and KST mildly bullish, but Bollinger Bands and Dow Theory both bearish on a monthly basis. <BR><BR>In terms of performance, the stock has returned 1.93% over the past month, which underperforms the S&P 500's 2.32% return, and year-to-date, it has gained 2.80% compared to the S&P 500's 15.47%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed signals across various indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROE of 22.80%

 
2

Company has a low Debt to Equity ratio (avg) at times

 
3

Flat results in Jun 25

4

With ROE of 15.23%, it has a fair valuation with a 4.62 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 48,455 Million (Mid Cap)

stock-summary
P/E

30.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.33

stock-summary
Return on Equity

14.74%

stock-summary
Price to Book

4.59

Revenue and Profits:
Net Sales:
1,532 Million
(Quarterly Results - Jun 2025)
Net Profit:
336 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.95%
0%
5.95%
6 Months
10.19%
0%
10.19%
1 Year
15.61%
0%
15.61%
2 Years
24.0%
0%
24.0%
3 Years
12.06%
0%
12.06%
4 Years
-20.93%
0%
-20.93%
5 Years
0.02%
0%
0.02%

Edwards Lifesciences Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Edwards Lifesciences Corp. Hits New 52-Week High at $87.09

Edwards Lifesciences Corp. Hits New 52-Week High at $87.09

Edwards Lifesciences Corp. achieved a new 52-week high of USD 87.09 on October 31, 2025, despite a one-year performance decline. With a market cap of USD 48,455 million, the company shows strong financial metrics, including a P/E ratio of 30.00 and a return on equity of 14.74%.

Read More
Edwards Lifesciences Corp. Hits New 52-Week High at $84.66

Edwards Lifesciences Corp. Hits New 52-Week High at $84.66

Edwards Lifesciences Corp. achieved a new 52-week high of USD 84.66 on October 29, 2025, despite a one-year performance decline of 3.96%. With a market cap of USD 48,455 million, the company has a P/E ratio of 30.00 and a return on equity of 14.74%.

Read More
Edwards Lifesciences Corp. Experiences Evaluation Revision Amid Mixed Market Performance Indicators

Edwards Lifesciences Corp. Experiences Evaluation Revision Amid Mixed Market Performance Indicators

Edwards Lifesciences Corp. has recently revised its evaluation amid changing market conditions. The stock is currently priced at $80.82, reflecting a notable increase. Technical indicators show mixed performance, with varying trends across different timeframes. The company's returns have lagged behind the S&P 500 over longer periods.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
5.64%
EBIT Growth (5y)
5.09%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.32
Sales to Capital Employed (avg)
0.69
Tax Ratio
10.93%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
93.32%
ROCE (avg)
29.61%
ROE (avg)
22.80%
Valuation key factors
Factor
Value
P/E Ratio
30
Industry P/E
Price to Book Value
4.62
EV to EBIT
29.18
EV to EBITDA
26.46
EV to Capital Employed
6.35
EV to Sales
7.86
PEG Ratio
20.62
Dividend Yield
NA
ROCE (Latest)
21.76%
ROE (Latest)
15.23%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 183 Schemes (35.81%)

Foreign Institutions

Held by 502 Foreign Institutions (32.22%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 8.46% vs 1.94% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -7.62% vs 5.39% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,532.20",
          "val2": "1,412.70",
          "chgp": "8.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "458.10",
          "val2": "436.30",
          "chgp": "5.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-60.00",
          "val2": "-26.40",
          "chgp": "-127.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "335.90",
          "val2": "363.60",
          "chgp": "-7.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "274.10%",
          "val2": "282.90%",
          "chgp": "-0.88%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.57% vs -6.92% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 14.43% vs -19.84% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,439.50",
          "val2": "5,010.00",
          "chgp": "8.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,599.50",
          "val2": "1,572.20",
          "chgp": "1.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "19.80",
          "val2": "17.60",
          "chgp": "12.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-41.60",
          "val2": "-163.40",
          "chgp": "74.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,396.00",
          "val2": "1,220.00",
          "chgp": "14.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "265.50%",
          "val2": "284.90%",
          "chgp": "-1.94%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
1,532.20
1,412.70
8.46%
Operating Profit (PBDIT) excl Other Income
458.10
436.30
5.00%
Interest
0.00
0.00
Exceptional Items
-60.00
-26.40
-127.27%
Consolidate Net Profit
335.90
363.60
-7.62%
Operating Profit Margin (Excl OI)
274.10%
282.90%
-0.88%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 8.46% vs 1.94% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -7.62% vs 5.39% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
5,439.50
5,010.00
8.57%
Operating Profit (PBDIT) excl Other Income
1,599.50
1,572.20
1.74%
Interest
19.80
17.60
12.50%
Exceptional Items
-41.60
-163.40
74.54%
Consolidate Net Profit
1,396.00
1,220.00
14.43%
Operating Profit Margin (Excl OI)
265.50%
284.90%
-1.94%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 8.57% vs -6.92% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 14.43% vs -19.84% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Edwards Lifesciences Corp. stock-summary
stock-summary
Edwards Lifesciences Corp.
Pharmaceuticals & Biotechnology
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.
Company Coordinates stock-summary
Company Details
1 Edwards Way , IRVINE CA : 92614-5688
stock-summary
Tel: 1 949 2502500
stock-summary
https://www.edwards.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."